CER Daily Newsfeed

Model N Rainmaker 2025 Recap

(5/29, John O’Brien, LinkedIn Post) comments “...Thanks #MNRAINMAKER25 for the opportunity to discuss the outlook for the future of the life sciences industry and to share what our research at the National Pharmaceutical Council is finding about: Early signals of the unintended consequences of the IRA impacting clinical development and research and patient access to today's treatments and tomorrow's cures. Increased health costs for employers, employees, states, and taxpayers thanks to growth of the 340B program. Manufacturers only receiving 50% of what we call drug spending in the US - but patients at the pharmacy counter not seeing those savings due to the arbitrage middlemen extract.” Full

5 Key Takeaways From ISPOR 2025: Advancing RWD & Patient-Centered Care

(5/29, Amplity) comments “...AI continues to drive innovation in RWD analysis, but ISPOR 2025 made one thing clear: its true power comes from the people behind it...One standout discussion explored how AI is being used for sentiment analysis in patient-reported outcomes (PROs). Sure, algorithms can dig up hidden insights in massive datasets, but it’s human experts who bring context, interpret the results, and turn them into actionable strategies. The takeaway? Innovation isn’t just about machines working faster or smarter—it’s about combining technology with human expertise and empathy. That’s how we ensure the insights we generate are not only effective but also meaningful and authentic.” Full

Methodological Advances and Stakeholder Insights in HTA: A Closer Look at NICE’s HTA Lab

(5/30, Katie McCool, The Evidence Base) reports “...Moderated by Jeanette Kusel (Programme Director of Methods, Research and Health Economics, NICE), the event featured insights from NICE, NHS England, the pharmaceutical industry, and academic collaborators. This article highlights the Lab’s objectives, key projects, stakeholder perspectives, and future areas of focus.” Full

Japan Price Cuts For Epkinly and Lunsumio Following CEA

(5/30, Lisa Takagi, Pink Sheet) reports “...Japan’s regulatory authorities have announced additional extraordinary reimbursement price cuts for several drugs following a Cost-Effectiveness Analysis (CEA) process, with Genmab’s T-cell-engaging bispecific antibody Epkinly (epcoritamab) and its competitor Chugai/Roche’s Lunsumio (mosunetuzumab) both facing a 2.7% cut on 1 August.” Subscription Required